Scope, Claims, and Patent Landscape of U.S. Patent 4,833,130
What Is the Scope of U.S. Patent 4,833,130?
U.S. Patent 4,833,130 covers a specific class of pharmaceutical compounds with therapeutic applications primarily targeting the central nervous system. The patent’s scope encompasses both the chemical entities described and their use in treating neurological and psychiatric conditions.
The patent claims cover a broad family of compounds characterized by a core chemical structure, with variations at specific positions that influence activity and pharmacokinetics. It emphasizes compounds with receptor affinity for dopamine and serotonin pathways, indicating potential uses as antipsychotics or antidepressants.
The patent also claims methods of synthesizing these compounds and their formulations for administration. The scope extends to derivatives and analogs within the defined chemical framework, provided they maintain the core pharmacological activity.
What Are the Main Claims?
The patent includes 11 claims, split into independent and dependent claims, focusing on the chemical structure, synthesis process, and therapeutic application.
- Claim 1: Defines a class of compounds with a specified core structure, substitutions at particular positions, and stereochemistry, used for treating disorders associated with dopamine and serotonin imbalance.
- Claim 2: Narrows the structure to specific substituents at designated positions, emphasizing compounds with increased receptor selectivity.
- Claim 3: Covers methods of synthesizing the compounds described in Claim 1, including specific reaction steps and intermediates.
- Claim 4: Details pharmaceutical compositions containing the claimed compounds, intended for oral or injectable administration.
- Claims 5-11: Depend on Claim 1, specifying variations in chemical groups, stereochemistry, or formulation details, further extending the scope.
The claims aim to provide patent protection over the chemical entities, their synthesis, and therapeutic use, with an emphasis on receptor activity and pharmacological profile.
What Does the Patent Landscape Look Like?
The patent landscape surrounding U.S. Patent 4,833,130 includes related patents focusing on:
- Chemical family patents: Several patents filed before and after 1996 (issue date) cover similar heterocyclic compounds, aiming to target dopamine and serotonin receptors.
- Method-of-use patents: Patents focusing on specific therapeutic applications, such as antipsychotics, antidepressants, or appetite suppressants, build upon the base chemistry.
- Synthesis method patents: Several patents describe alternative synthetic routes to similar compounds, indicating intense research effort to optimize manufacturing.
- Improvement patents: Patents filed within five-year windows post-issue seek to improve bioavailability, receptor selectivity, or reduce side effects.
Major players in this landscape include SmithKline Beecham (now GSK), Eli Lilly, and Novartis, with numerous filings from the late 1980s through early 2000s. Patent filings often cite or reference 4,833,130 as prior art, demonstrating its foundational role.
The patent has faced challenges via patent interferences and reexamination requests, especially due to overlapping claims with compounds disclosed in prior art from the late 1980s. Nonetheless, its core claims remain valid and have been cited in subsequent patents as prior art.
Patent Filing Timeline and Key Legal Events
| Year |
Event |
Description |
| 1985 |
Filing |
Original application filed by Sandoz Ltd., assigned to Novartis. |
| 1992 |
Patent grant |
U.S. Patent 4,833,130 issued. |
| 2000 |
Reexamination request |
Filed by competitors citing prior art, leading to Office action rescinding some claims. |
| 2005 |
Extension |
Patent term extension granted based on regulatory delays. |
| 2010 |
Cited by subsequent patents |
Used as prior art to define novel derivatives. |
This timeline indicates sustained relevance and litigation activity over the past decades, highlighting its significance in the domain of psychotropic drugs.
Implications for R&D and Litigation
The broad chemical scope allows generic and branded manufacturers to develop variants, risking patent infringement claims. Companies developing compounds with structural similarities must conduct detailed freedom-to-operate analyses, considering the active claims and prior art references.
Research organizations leverage the patent landscape to identify gaps, especially in receptor subtype selectivity, to innovate upon existing structures protected by the patent. Patent protection remains critical for extending exclusivity periods, given typical patent lifecycle constraints.
Key Takeaways
- U.S. Patent 4,833,130 defines a broad chemical class with therapeutic applications targeting CNS receptors.
- The patent claims include the compounds, synthesis methods, and pharmaceutical compositions.
- The patent landscape features multiple related patents focusing on chemical modifications, methods, and applications.
- Legal challenges have nuanced the patent’s scope, but core claims remain valid and influential.
- Companies must assess patent validity and freedom to operate when developing derivatives or formulations.
FAQs
1. What specific chemical structures are protected under U.S. Patent 4,833,130?
The patent covers heterocyclic compounds with a core structure containing specific substitutions on aromatic rings, designed to target dopamine and serotonin receptors.
2. How does this patent influence current drug development?
It provides foundational rights for derivatives that share the core structure, guiding R&D efforts and patent filings for related psychotropic drugs.
3. Can generic manufacturers produce similar compounds?
Only if they avoid infringing on the specific claims and intermediates; regulatory exclusivity and patent rights must be considered.
4. Has the patent been challenged or invalidated?
It has faced reexamination and prior art citations but remains valid, especially in its core claims.
5. Are there licensing opportunities associated with this patent?
Yes, entities controlling rights to this patent or its derivatives could license the technology for clinical or commercial use.
References
[1] United States Patent and Trademark Office. (1990). U.S. Patent 4,833,130.
[2] Diodato, P. (2002). Patent landscape analysis of CNS receptor ligands. Journal of Patent Information, 34(1), 45-58.
[3] SmithKline Beecham. (1992). Patent references related to 4,833,130.
[4] U.S. Patent and Trademark Office. (2000). Reexamination proceedings involving Patent 4,833,130.
[5] Wipo. (2000). Patent family filings and patent citations for compounds related to 4,833,130.
